Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
1.690
-0.085 (-4.79%)
At close: Nov 6, 2026, 4:00 PM EST
1.747
+0.057 (3.39%)
Pre-market: Nov 9, 2026, 4:11 AM EST
Evotec SE Revenue
Evotec SE had revenue of 164.93M EUR in the quarter ending September 30, 2026, with 0.63% growth. This brings the company's total for the last twelve months to 718.32M, down -5.03% year-over-year. In the year 2025, Evotec SE had annual revenue of 788.37M, down -1.08%.
Revenue (ttm)
718.32M EUR
Revenue Growth
-5.03%
P/S Ratio
0.77
Revenue / Employee
161,023 EUR
Employees
4,461
Market Cap
627.05M USD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Evotec SE breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 788.37M | -8.59M | -1.08% |
| Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
| Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | 446.44M | 71.03M | 18.92% |
| Dec 31, 2018 | 375.41M | 111.64M | 42.33% |
| Dec 31, 2017 | 263.77M | 99.26M | 60.34% |
| Dec 31, 2016 | 164.51M | 36.83M | 28.85% |
| Dec 31, 2015 | 127.68M | 38.18M | 42.66% |
| Dec 31, 2014 | 89.50M | 3.56M | 4.14% |
| Dec 31, 2013 | 85.94M | -1.33M | -1.52% |
| Dec 31, 2012 | 87.27M | 7.14M | 8.91% |
| Dec 31, 2011 | 80.13M | 24.87M | 45.00% |
| Dec 31, 2010 | 55.26M | 12.58M | 29.47% |
| Dec 31, 2009 | 42.68M | 3.07M | 7.75% |
| Dec 31, 2008 | 39.61M | -14.77M | -27.16% |
| Dec 31, 2007 | 54.38M | -30.30M | -35.78% |
| Dec 31, 2006 | 84.68M | 4.90M | 6.14% |
| Dec 31, 2005 | 79.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 963.10M |
| Collegium Pharmaceutical | 815.19M |
| Amphastar Pharmaceuticals | 745.79M |
| Emergent BioSolutions | 649.10M |
| Ironwood Pharmaceuticals | 400.30M |
| Evolus | 325.47M |
| Harrow | 275.59M |
| Aurora Cannabis | 221.16M |
EVO News
- 2 days ago - Evotec price target raised to $5 from $4 at H.C. Wainwright - TheFly
- 3 days ago - Evotec SE (EVO) Q3 2026 Earnings Call Transcript - The Motley Fool
- 3 days ago - What Evotec (EVO) Said on Its Q3 Earnings Call - MarketBeat
- 3 days ago - Evotec Reports Q3 EBITDA Improvement; Reaffirms FY26 Guidance And Outlines 2030 Growth Targets - Nasdaq
- 3 days ago - Evotec SE Earnings Call Transcript: Q3 2026 - Transcripts
- 3 days ago - Evotec SE Quarterly report: Q3 2026 - Filings
- 3 days ago - Evotec SE Slides: Q3 2026 - Filings
- 4 days ago - Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals - PRNewsWire